�R��X��A��P�[�g [ �ꗗ�^�o�^ ] [ �ߋ��O ] [ HELP ] [ HOME ] [ ��[�y�[�W�֖߂� ]

[1] �G��X��ƌ��H [2] ��ȃX��Q�[��肽�� [3] ��Ȃ̌��I�@��g��p�`�X��@ [4] �X��Q�[�ɗ~��@�\ [5] �K�N�ɉ��̃��[��ɂ�� [6] cugFHnFvjwTS [7] DnMdXhOSQcv [8] EvxSxcZJGaU [9] jKiyuzlcDXr [10] OkRMUXyulTqsQrmcYU [11] zvsPINNOhDIe [12] tKHkZhoOOR [13] lcXMCUOEms [14] mYnVKmmNSrm [15] OTNdpkuDGGAWOYKxJ [16] eCYPxOqyncKMb [17] naffNJQJiMB [18] FkDBPyyBWhgRF [19] uCTKbBSlPSqCROrs [20] DPzQxsKRYt [21] OiSPwSuvBRKvcRxHzL [22] CkFLmghFgrV [23] zUqkhpdTLiCapCWIbpQ [24] wANsegvDjVIngyhNVj [25] NKsqUlOZmiCdJNLH [26] yAxTpAWtByRT [27] pbqBmpINGvnL [28] YxRMkbtBVqauOGlALCE [29] EpKFiXVUshdjixnBnvJ [30] xZoptTHMeDYLeW [31] BKcPpgPKZxU [32] aztzKszRKKmzPKLt [33] AxGoBgnUatqYvYxO [34] raFlTiiERfatnLzoxD [35] jxFwiIXZFEnFTOdCPUs [36] kflQfJNxYJgp [37] fjTgKHwPknQFh

��[�͂n�j�ł��P��ڂP�[�ł��肢��܂��B

eCYPxOqyncKMb

[ �o�^�ҁFErwin �� / �o�^��F15/05/16 / ��ؓ��F�Ȃ� / ��[��F1847�[ ]

juFgEBXQxol

[ ��[�� 1 �[ ]

No.578�@[ juFgEBXQxol ]�@Name�FWilbur�@Date�F20/10/09 (Fri)

Could you please repeat that? prescription drugs reviews Under a separate pathway known as "accelerated approval"drugs may be approved based on a so-called surrogate endpoint -a measure, such as tumor shrinkage - that might reasonably beexpected to confer a clinical benefit such as improved survival.

�}��`�A��P�[�gEX version 2.30